Superstock Investor
Member Login   RSS ->
James DiGeorgia, Mr. Macro
- Chief Editor -
Mr. Macro
Geoff Garbacz, Mr. Micro
- Chief Strategist -
Mr. Micro
Dan Hassey, Mr. Retirement
- Senior Stock Analyst -
Mr. Retirement
Superstock Investor

[Printable Version of This Page]

Today's Superstock Investor Stock Scorecard:

Celgene Corporation (CELG)
by Superstock Investor

January 3, 2019


Bristol Myers (BMY) is buying Celgene (CELG) for $102.43. So how did our price target and upper bound do on this purchase? The model tells us that Bristol Myers is overpaying by $20 a share. Maybe that is why Bristol Myers is lower by 15%.

Company Information

Company: Celgene Corporation
Sector: Pharmaceuticals
Industry: Biotechnology
Market Cap:  $68,460,193,500


  Price %Gain  
Current Price $73.42    
Price Target $66.08 -10.0%  
Upper Bound $82.60 12.5%  
Lower Bound $56.17 -23.5%  

Stock data last updated 12/03/2018.

Data provided by QPI, Inc. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. QPI, Inc. is not liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing this page, you agree not to redistribute the information found herein.

Stock Scorecard Archives